Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis
- 17 May 2016
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 35 (8) , 1985-1991
Abstract
Glucocorticoids (GC) are widely used to treat systemic sclerosis (SSc). The lack of efficacy data and patient/physician concerns may prompt therapy discontinuation. The aim of this study is to identify factors hampering GC discontinuation in patients with stable disease on oral GC for longer than 12 months. Consecutive patients fulfilling the 2013 ACR/EULAR criteria for SSc and with stable disease were prescribed a slow tapering GC regimen to achieve discontinuation. At study entry and 6 months later (T6), patients were assessed for disease activity and severity. Moreover, the Short-Form-36; the Health Assessment Questionnaire Disability Index (HAQ-DI); and visual analog scales for fatigue, pain, and general health were completed. Reasons for stopping the discontinuation regimen were recorded. Forty-eight patients (46 females, 9 diffuse SSc), with a mean ± SD age of 56±14 years and a median disease duration of 10 years (range 2–22), were enrolled. The median daily GC dose was 5 mg (range 5–10; all patients treated with prednisone). At T6, 33 (68.7 %) patients had discontinued GC. The remaining 15 patients could not discontinue GC because of arthralgia in eight, arthritis in two, puffy fingers in two, increased creatine-kinase in two, and bursitis in one patient. At multiple logistic analysis, a higher baseline HAQ-DI was the only independent factor associated with GC need (OR 2.98, 95 % CI 1.20–7.41; p = 0.01). About one third of SSc patients did not achieve a GC-free regimen. Disability as assessed by HAQ-DI was the leading factor hindering GC discontinuation. A low HAQ-DI score can identify candidates for GC discontinuation.Keywords
This publication has 47 references indexed in Scilit:
- Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal?2013
- Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markersArthritis Research & Therapy, 2013
- Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal studyRheumatology, 2011
- Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practiceAnnals of the Rheumatic Diseases, 2010
- Ultrasonographic features of the hand and wrist in systemic sclerosisRheumatology, 2009
- EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)Annals of the Rheumatic Diseases, 2009
- The effect of moderate‐dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2006
- Prolonged remission in systemic lupus erythematosus.2005
- Scleroderma renal crisisRheumatic Disease Clinics of North America, 2003
- Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional studyBMJ, 1996